Prognostic Value of Interim [ 18 F]FDG PET in Large B-Cell Lymphoma: A Systematic Review and Meta-analysis with a Particular Focus on Interim Deauville Score 5 Disease
Journal of Nuclear Medicine · 2026-04 · 67 (4) · 514-520
DOI: 10.2967/jnumed.125.271089 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 16.01.2026. Verfasst von Seyed Ali Mirshahvalad und 5 weiteren Autor:innen. Beteiligte Einrichtung: University Medical Imaging Toronto, Joint Department of Medical Imaging, University Health Network, Sinai Health System and Women's College Hospital,…. Hauptthemen laut MEDLINE: Fluorodeoxyglucose F18, Positron-Emission Tomography, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 62 Literaturangaben.
Abstract (Originalsprache)
Our rationale was to investigate the potential of interim [18F]FDG PET (iPET) in predicting large B-cell lymphoma (LBCL) patients' outcomes, including the end-of-treatment response, progression-free survival (PFS), and overall survival (OS).
Methods
A systematic search was conducted on the 3 main medical literature databases until January 8, 2025. Published original articles that evaluated iPET for prognosticating LBCL patients and provided crude data for meta-analytic calculations were considered eligible. The hierarchic method was used to pool the random-effect model's end-of-treatment prediction performance measures of sensitivity, specificity, positive likelihood ratio (LR), and negative LR. The bivariate model was used to determine the corresponding 95% CI. Furthermore, PFS and OS were pooled across studies, including survival proportions and hazard ratios (HRs). All analyses were conducted using STATA 16 software.
Results
The initial search resulted in 939 studies. After the full-text review, 44 studies were considered eligible. The pooled sensitivity and specificity of iPET for predicting end-of-treatment response were 0.78 (95% CI, 0.69-0.84) and 0.84 (95% CI, 0.78-0.88), respectively. On the basis of the pooled positive and negative LRs, iPET was not a reliable modality to exclude or confirm the end-of-treatment [18F]FDG PET results. The pooled PFS HR across all available datasets (n = 27) was 2.88 (95% CI, 2.35-3.52) for positive iPET (Deauville score [DS] 4-5). In datasets with HRs for positive iPET versus DS 5 alone, the pooled HRs were 2.36 (95% CI, 1.74-3.21) versus 5.59 (95% CI, 4.35-7.19). Furthermore, when datasets were limited to those with data on change in SUVmax versus DS 5 (n = 6), the pooled HRs were 3.41 (95% CI, 2.67-4.35) versus 5.59 (95% CI, 4.35-7.19), respectively. The pooled OS HR across all available datasets (n = 22) was 3.71 (95% CI, 2.93-4.69) for positive iPET. In datasets with HRs for positive iPET versus DS 5 alone (n = 5), the pooled HRs were 3.31 (95% CI, 2.09-5.24) versus 8.10 (95% CI, 6.04-10.85). Moreover, when datasets were limited to those with data on change in SUVmax versus DS 5 (n = 5), the pooled HRs were 4.54 (95% CI, 3.57-5.78) versus 8.10 (95% CI, 6.04-10.85).
Conclusion
On the basis of our comprehensive systematic review and meta-analysis, DS 5 is a highly reliable predictor of unfavorable response to therapy on iPET. The utility of this threshold to escalate or modify therapy needs to be evaluated in future prospective trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University Medical Imaging Toronto, Joint Department of Medical Imaging, University Health Network, Sinai Health System and Women's College Hospital, Toronto, Ontario, Canada; smirshahvalad@hsnsudbury.ca.
- Department of Medical Imaging, Health Sciences North, Northern Ontario School of Medicine, Sudbury, Ontario, Canada; and.
- Division of Hematology and Medical Oncology, Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
- University Medical Imaging Toronto, Joint Department of Medical Imaging, University Health Network, Sinai Health System and Women's College Hospital, Toronto, Ontario, Canada.
Zitieren
APA
Mirshahvalad, S. A., Hodgson, D., Kuruvilla, J., Veit-Haibach, P., Ortega, C., & Metser, U. (2026). Prognostic Value of Interim [ 18 F]FDG PET in Large B-Cell Lymphoma: A Systematic Review and Meta-analysis with a Particular Focus on Interim Deauville Score 5 Disease. Journal of Nuclear Medicine, 67(4), 514-520. https://doi.org/10.2967/jnumed.125.271089
Vancouver
Mirshahvalad SA, Hodgson D, Kuruvilla J, Veit-Haibach P, Ortega C, Metser U. Prognostic Value of Interim [ 18 F]FDG PET in Large B-Cell Lymphoma: A Systematic Review and Meta-analysis with a Particular Focus on Interim Deauville Score 5 Disease. Journal of Nuclear Medicine. 2026;67(4):514-520. doi:10.2967/jnumed.125.271089
BibTeX
@article{Mirshahvalad2026,
author = {Mirshahvalad, Seyed Ali and Hodgson, David and Kuruvilla, John and Veit-Haibach, Patrick and Ortega, Claudia and Metser, Ur},
title = {Prognostic Value of Interim [ 18 F]FDG PET in Large B-Cell Lymphoma: A Systematic Review and Meta-analysis with a Particular Focus on Interim Deauville Score 5 Disease},
journal = {Journal of Nuclear Medicine},
year = {2026},
volume = {67},
number = {4},
pages = {514--520},
doi = {10.2967/jnumed.125.271089}
}
EUVIMED